NCT04080531 · OUTCOME

Seroprotection Based on Hemagglutination Antibody Inhibition (HAI)

Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders · Source last updated 2025-02-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 21 weeks

What was measured

HAI in blood at week 21 for all variants

Groups in this outcome

Arm I (Trivalent Influenza Vaccine, Prevnar)

Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity. Pneumococcal 13-valent Conjugate Vaccine: Given IM Trivalent Influenza Vaccine: Given IM

Arm II (Trivalent Influenza Vaccine, Prevnar)

Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity. Pneumococcal 13-valent Conjugate Vaccine: Given IM Trivalent Influenza Vaccine: Given IM

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm I (Trivalent Influenza Vaccine, Prevnar)	80
Arm II (Trivalent Influenza Vaccine, Prevnar)	85

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm I (Trivalent Influenza Vaccine, Prevnar)	32	Not reported	Not reported	Not reported	Not reported
Arm II (Trivalent Influenza Vaccine, Prevnar)	22	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
32
group Id
OG001
value
22

denoms

counts
group Id
OG000
value
80
group Id
OG001
value
85
units
Participants

description

HAI in blood at week 21 for all variants

groups

description
Patients receive trivalent influenza vaccine IM at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity. Pneumococcal 13-valent Conjugate Vaccine: Given IM Trivalent Influenza Vaccine: Given IM
id
OG000
title
Arm I (Trivalent Influenza Vaccine, Prevnar)
description
Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity. Pneumococcal 13-valent Conjugate Vaccine: Given IM Trivalent Influenza Vaccine: Given IM
id
OG001
title
Arm II (Trivalent Influenza Vaccine, Prevnar)

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

21 weeks

title

Seroprotection Based on Hemagglutination Antibody Inhibition (HAI)

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice